Loading...
Market
How will Lundbeck's neuroscience pipeline be impacted by the acquisition by the end of 2025?
2
Resolution / Starting Odds
Significant enhancement • 25%
Moderate enhancement • 25%
No change • 25%
Negative impact • 25%
Official reports or press releases from Lundbeck
Story
Lundbeck to Acquire Longboard Pharmaceuticals for $2.6 Billion at $60/Share, 77% Premium
Oct 14, 2024, 12:13 PM
Lundbeck, a Danish pharmaceutical company, has announced its acquisition of Longboard Pharmaceuticals for $2.6 billion. The deal values Longboard at $60 per share, representing a 77% premium to its volume-weighted average price. This acquisition is expected to significantly enhance Lundbeck's neuroscience pipeline, particularly in the area of neuro-rare treatments, including a Phase 3 drug for Dravet syndrome. The transaction has been unanimously approved by the boards of both companies and is anticipated to close in the fourth quarter of 2024, pending regulatory approvals. Centerview LLC advised on the deal. Longboard's stock surged by over 50% in pre-market trading following the announcement.
View original story
Similar markets
Significant enhancement in neuroscience pipeline • 25%
Moderate enhancement • 25%
No significant change • 25%
Negative impact • 25%
Significant growth (>10%) • 25%
Moderate growth (5-10%) • 25%
Minimal growth (<5%) • 25%
No growth or decline • 25%
On time (by Q4 2024) • 25%
Delayed to Q1 2025 • 25%
Delayed to Q2 2025 or later • 25%
Deal Cancelled • 25%
Lundbeck's stock rises over 5% • 25%
Lundbeck's stock falls over 5% • 25%
Longboard's stock remains stable • 25%
Other • 25%
1 new acquisition • 25%
2 new acquisitions • 25%
3 new acquisitions • 25%
4 or more new acquisitions • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No changes • 25%
Minor changes • 25%
Major changes • 25%
Complete overhaul • 25%
Yes • 50%
No • 50%
Significant positive impact • 25%
Moderate positive impact • 25%
No significant impact • 25%
Negative impact • 25%